3,7,12-trihydroxycholestan-26-oic acid has been researched along with clofibric acid in 1 studies
| Studies (3,7,12-trihydroxycholestan-26-oic acid) | Trials (3,7,12-trihydroxycholestan-26-oic acid) | Recent Studies (post-2010) (3,7,12-trihydroxycholestan-26-oic acid) | Studies (clofibric acid) | Trials (clofibric acid) | Recent Studies (post-2010) (clofibric acid) |
|---|---|---|---|---|---|
| 31 | 0 | 0 | 1,429 | 103 | 120 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farrants, AK; Nilsson, A; Pedersen, JI | 1 |
1 other study(ies) available for 3,7,12-trihydroxycholestan-26-oic acid and clofibric acid
| Article | Year |
|---|---|
Human hepatoblastoma cells (HepG2) and rat hepatoma cells are defective in important enzyme activities in the oxidation of the C27 steroid side chain in bile acid formation.
Topics: Animals; Bile Acids and Salts; Chenodeoxycholic Acid; Cholestanols; Cholesterol 7-alpha-Hydroxylase; Cholic Acid; Cholic Acids; Clofibric Acid; Dexamethasone; Fatty Acids; Hepatoblastoma; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Oxidation-Reduction; Rats; Rats, Wistar; Retinoids; Tumor Cells, Cultured | 1993 |